JPWO2021092322A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021092322A5
JPWO2021092322A5 JP2022526226A JP2022526226A JPWO2021092322A5 JP WO2021092322 A5 JPWO2021092322 A5 JP WO2021092322A5 JP 2022526226 A JP2022526226 A JP 2022526226A JP 2022526226 A JP2022526226 A JP 2022526226A JP WO2021092322 A5 JPWO2021092322 A5 JP WO2021092322A5
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
subject
cell
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553865A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/059329 external-priority patent/WO2021092322A1/en
Publication of JP2022553865A publication Critical patent/JP2022553865A/ja
Publication of JPWO2021092322A5 publication Critical patent/JPWO2021092322A5/ja
Pending legal-status Critical Current

Links

JP2022526226A 2019-11-06 2020-11-06 がん幹細胞を標的化するがん治療 Pending JP2022553865A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962931531P 2019-11-06 2019-11-06
US62/931,531 2019-11-06
PCT/US2020/059329 WO2021092322A1 (en) 2019-11-06 2020-11-06 Cancer treatments targeting cancer stem cells

Publications (2)

Publication Number Publication Date
JP2022553865A JP2022553865A (ja) 2022-12-26
JPWO2021092322A5 true JPWO2021092322A5 (zh) 2023-11-14

Family

ID=73643356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526226A Pending JP2022553865A (ja) 2019-11-06 2020-11-06 がん幹細胞を標的化するがん治療

Country Status (12)

Country Link
US (1) US20230023124A1 (zh)
EP (1) EP4055008A1 (zh)
JP (1) JP2022553865A (zh)
KR (1) KR20220110744A (zh)
CN (1) CN114929672A (zh)
AU (1) AU2020378067A1 (zh)
BR (1) BR112022008753A2 (zh)
CA (1) CA3157315A1 (zh)
CO (1) CO2022007910A2 (zh)
IL (1) IL292718A (zh)
MX (1) MX2022005445A (zh)
WO (1) WO2021092322A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518089A (ja) * 2021-05-13 2024-04-24 リメディー プラン,インコーポレーテッド Nampt阻害剤とその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
WO2008016643A2 (en) * 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
WO2008026018A1 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
FR2921657A1 (fr) * 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
EP2866791A4 (en) 2012-05-07 2016-04-20 Gen Hospital Corp NOVEL COMPOSITIONS AND USES BLOOD PRESSURE RECIPROCATORS FOR CANCER THERAPY
US9381253B2 (en) 2013-04-09 2016-07-05 Massachusetts Institute Of Technology Drug delivery polymer and uses thereof
CN112312899A (zh) * 2018-05-04 2021-02-02 治疗方案股份有限公司 靶向癌症干细胞的癌症治疗

Similar Documents

Publication Publication Date Title
DE60316542T2 (de) 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen
EP4328224A1 (en) Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
RU2683566C1 (ru) Производное с сочлененными кольцами и способ его получения, промежуточное соединение, фармацевтическая композиция и их применение
JP2018510184A5 (zh)
US9266897B2 (en) Derivatives of protoberberine biological alkaloids and use of same inhibiting ulcerative colitis
JP7222590B2 (ja) 3-アザビシクロ[3,1,1]ヘプタン誘導体及びこれを含む薬学的組成物
JPH04230389A (ja) ラパマイシン誘導体
TWI706951B (zh) 一種週期素依賴性蛋白激酶抑制劑的羥乙基磺酸鹽、其結晶形式及製備方法
AU2009260060B2 (en) Thiazolyl- and oxazolyl-isoquinolinones and methods for using them
US20230109134A1 (en) Pyridazinone or pyridazine compound and derivative and pharmaceutical composition thereof
JP2023548148A (ja) 置換ピラゾロピリミジンの固体形態及びその使用
JP2017510657A (ja) Mif阻害剤
JPWO2021092322A5 (zh)
JP5378499B2 (ja) 微小管形成阻害剤として有用なベンゾフェノンチアゾール誘導体及びその製造方法
JP2023511302A (ja) 新規なピラゾール誘導体
CN111718350A (zh) 吡唑取代的吡唑并嘧啶化合物和药物组合物及其应用
CN107778336B (zh) 吡喃葡萄糖基衍生物的结晶形式
WO2021073498A1 (zh) Egfr抑制剂、组合物及其制备方法
AU2009259980B2 (en) Thienyl- and furanyl-isoquinolinones and methods for using them
CN115667254A (zh) 作为溴结构域蛋白质抑制剂的化合物和组合物
JP2023505238A (ja) 新規ピロール化合物
TWI843806B (zh) 作為nrf2活化劑之羥基吡啶并氧氮呯
WO2024143236A1 (ja) 酢酸エステル塩酸塩の結晶
WO2020156150A1 (zh) 泊马度胺前体药物盐的多晶型物
JP7125714B2 (ja) 抗ウイルス活性を有する2’-デオキシ-7-デアザプリンヌクレオシド誘導体